Media Coverage

Merck targets swine combination vaccines with latest patent applications


Oct 31, 2017 - Animal Pharm
By Joseph Harvey
Animal Pharm
October 31, 2017


Merck Animal Health has supported its vaccine portfolio by applying for patents covering prevention of three of the most economically-damaging swine diseases.

In WO2017162741 Merck claims a combination vaccine against porcine circovirus 2 (PCV2) virus and Mycoplasma hyopneumoniae infection. Vaccines for both pathogens are commercially available. However, according to the patent application, there is no efficacious and safe combination vaccine available for intradermal administration.

Merck applied for two additional patents to cover vaccine work for PCV2 and porcine reproductive and respiratory syndrome (PRRS) – another area in need of a combination preventative. In WO2017162727 Merck claims a combination vaccine against PCV2 and PRRS virus infection comprising albumin. In WO2017162720 Merck claims a vaccine for intradermal application against PCV2 and PRRS virus infection.

The firm's swine health offering features Circumvent PCV G2, which is the only PCV2 vaccine approved in the US for use in pigs as early as three days of age.

According to the Animal Pharm Patent Archive, other companies with multiple new patent applications in September were Bayer Animal Health, Boehringer Ingelheim Vetmedica, Ceva Santé Animale, Merial and Zoetis.

AAD, IDEXX claim diagnostics patents

In WO2017165570 Advanced Animal Diagnostics (AAD) claims methods and compositions for reducing antibiotic administration to farm animals.

The patent application states: "Livestock producers have few tools to identify which animals need treatment; it is difficult to distinguish infected animals that benefit from antibiotic treatment from those that are not infected. As animals are co-mingled, they are more likely to become infected, but infected animals may be difficult to distinguish from uninfected animals based on temperature or antibody response, especially if the exposure was recent."

AAD's claims its invention provides a method of identifying an appropriate animal for treatment with antibiotics, anti-infectives, probiotics or immunostimulants.

This technique comprises: collecting a sample from the animal; performing a leukocyte differential cell count on said sample; comparing said leukocyte differential cell count with an index of infection; and initiating treatment.

In US2017269101 IDEXX claims a method for the detection and diagnosis of renal disease and periodontal disease in mammals. Early-stage detection of both these diseases are required for companion animals. In the case of renal disease, by the time clinical symptoms develop, irreparable kidney damage can occur.

Current methods for detecting renal disease in mammals include kidney ultrasound, biopsy, or measurement of urine protein/creatinine levels. However, biopsies are invasive and creatinine measurement is not accurate until stage three of renal failure, which can be after significant tissue damage has occurred.

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum